CNOGA Medical Ltd.
Israeli digital-health company behind the noninvasive Smart Capsule™ wearable sensor and cuff-free blood-monitoring devices.
Last updated September 28, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
CNOGA Medical Ltd. is an Israeli digital-health company based in Caesarea that develops noninvasive blood-parameter monitoring devices. Its product family is built around optical, thermal and bioimpedance sensing combined with machine-learning and cloud computing, allowing biomarkers and vital signs to be estimated from the body without drawing blood or using a cuff. The company states it has a 10-year presence in the noninvasive glucose-monitoring market, an extended patent portfolio and investments of over $70 million. CNOGA's flagship concept is the Smart Capsule™, described as a truly noninvasive glucometer and blood-biomarker wearable sensor. The capsule integrates the company's patent-pending M-Safe™ (Multi-Sensors Adaptive Fusion Ensemble) technology, which captures optical, thermal and bioimpedance signals; through complex machine-learning models, AI and cloud computing it estimates multiple bio-parameters from the wrist. It can be worn on a dedicated CNOGA wristband or integrated into third-party smartwatches, and it is designed for OEM deployment and connection to telemedicine platforms or apps. The company says the Smart Capsule™ is based on its clinically proven first-generation products, which have been medically certified and approved for marketing in Europe, Israel, Brazil and China. Alongside the capsule, CNOGA markets the MTX device, a semi-continuous, noninvasive and cuff-free blood-pressure monitor that also measures hemoglobin, hematocrit and red blood cells, blood gases (pH, PCO2, PO2, O2 and CO2 content), cardiac output, stroke volume and mean arterial pressure, with Bluetooth and cloud connectivity. The company also promotes a CoG glucometer concept aimed at freeing diabetics from frequent finger pricks, and a Health Point / health-station concept for check-up points in public and retail locations. CNOGA positions itself across diabetics, chronic-patient monitoring, wellness, blood banks and remote patient monitoring. Its stated expertise areas are connectivity, sustainability and personalization. The company has run projects such as MTX deployment in community clinics in Cascavel, Brazil, and a remote-monitoring "Talisman" project in the Puglia region of Italy, and it has promoted a Covid-19 monitoring solution for shifting care to home and remote settings. It warns customers about counterfeit CNOGA Medical products sold through unauthorized websites.
History
CNOGA Medical Ltd. is an Israeli medical-technology company headquartered in Caesarea. Public information about its founding date and founders is limited in the available evidence; the company itself states it has had a 10-year presence in the noninvasive glucose-monitoring market, which places its commercial activity in this field at roughly a decade before the current product generation. The company reports an extended patent portfolio and cumulative investments of over $70 million, alongside hundreds of R&D man-hours, as the foundation for its sensing and algorithmic platform. CNOGA's technology approach is to combine multiple physical sensing modalities — optical, thermal and bioimpedance signals — and to interpret them with machine-learning models, AI and cloud computing. This platform, branded M-Safe™ (Multi-Sensors Adaptive Fusion Ensemble) and described as patent-pending, is the basis for estimating multiple bio-parameters from the wrist. The company's first-generation products were medically certified and approved for marketing in Europe, Israel, Brazil and China, giving CNOGA a regulatory footprint across several major regions. Building on that first generation, CNOGA developed the Smart Capsule™, a wearable sensor positioned as a truly noninvasive glucometer and blood-biomarker device. The capsule can be worn on a dedicated CNOGA wristband or integrated into third-party smartwatches, and it is offered as a customizable core ready for OEM deployment and connection to telemedicine platforms or apps. The company presents the capsule as consolidating its unique technology and enabling noninvasive sugar measurement with reliable display of eight bio-parameters on any platform. In parallel, CNOGA markets the MTX device, a semi-continuous, noninvasive and cuff-free blood-pressure monitor that also measures hemoglobin, hematocrit and red blood cells, blood gases (pH, PCO2, PO2, O2 and CO2 content), cardiac output, stroke volume and mean arterial pressure, with Bluetooth and cloud connectivity. The company also promotes a CoG glucometer concept aimed at eliminating frequent finger pricks for diabetics, and a Health Point health-station concept developed in connection with the Italian company Health Italy to place check-up points in town squares, shopping centers and urban centers. CNOGA has pursued international projects and partnerships. It has worked on MTX deployment in community clinics in Cascavel, Brazil, where patients otherwise travel many hours by bus to reach the nearest regional hospital. In Italy, it has been involved in the Talisman remote-monitoring project and a portable mini lab in the Puglia region, and it has appeared in the CICC Innovation Lounge. During the Covid-19 pandemic period, the company promoted a Covid-19 monitoring solution oriented toward homecare and remote monitoring of critical parameters in 30 seconds and 16 bio-parameters in 60 seconds. CNOGA also warns customers about counterfeit CNOGA Medical products sold through unauthorized websites, indicating an active brand-protection concern.
CNOGA states a 10-year presence in the noninvasive glucose-monitoring market, with an extended patent portfolio and over $70M invested.
[1]First-generation CNOGA products receive medical certification and marketing approval in Europe, Israel, Brazil and China.
[2]CNOGA develops the Smart Capsule™ wearable sensor based on its first-generation technology, integrating M-Safe™ and ready for OEM deployment.
[2]MTX deployed in community clinics in Cascavel, Brazil, as an ongoing project.
[1]Talisman remote-monitoring project and portable mini lab in the Puglia region of Italy.
[1]CNOGA promotes a Covid-19 monitoring solution for homecare and remote monitoring.
[3]
Products and positioning
Noninvasive, cuff-free and needle-free digital monitoring of blood biomarkers and vital signs for diabetics, chronic patients, wellness, blood banks and remote care.
Smart Capsule™
A noninvasive glucometer and blood-biomarker wearable sensor integrating M-Safe™ technology; captures optical, thermal and bioimpedance signals and estimates multiple bio-parameters from the wrist via machine learning, AI and cloud computing. Can be worn on a CNOGA wristband or integrated into smartwatches, and is ready for OEM deployment.
MTX
A semi-continuous, noninvasive and cuff-free blood-pressure monitor that also measures hemoglobin, hematocrit and RBC, blood gases (pH, PCO2, PO2, O2 and CO2 content), cardiac output, stroke volume and MAP, with Bluetooth and cloud connectivity.
CoG Glucometer
A glucometer concept aimed at freeing diabetics from frequent finger pricks for blood-sugar measurement.
Health Point health station
A check-up health point concept developed with the Italian company Health Italy, intended for town squares, shopping centers and urban centers.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/cnoga-medical-ltd-israel · Editorial policy · How profiles are compiled